Improving Glioblastoma Management: A Study of Biomarkers, Tumor Microenvironment and Chemoresistance

Abstract

Glioblastoma (GBM) is an aggressive form of adult brain tumors. The current standard of care includes maximal safe resection followed by concurrent chemo-radiation therapy and adjuvant chemotherapy with temozolomide. Despite advances in biology and treatment modalities, the prognosis of GBM remains poor. The research in the field of GBM management includes finding factors which can be utilized to improve diagnosis and prognosis, also to reduce chemoresistance. Utilizing proteomics and genomics approaches we investigated the role of biomarkers, tumor microenvironment and factors responsible for chemoresistance